Engineered Probiotics for Treatment and Immunity Against Viruses

Tue, 21 Apr 2026 10:47:50 +0000
Intellectual Property

The USPTO granted Patent US12605413B2 to the University of Cincinnati covering an engineered probiotic bacterium comprising heterologous nucleic acid encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917 with the nanobody appearing on the bacterial surface. The patent contains 9 claims and was filed on April 19, 2021.